Safety and tolerability of flexible dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder
Jan K Buitelaar1, J Antoni Ramos-Quiroga2, Miguel Casas2, J J Sandra Kooij3, Asko Niemelä4, Eric Konofal5, Joachim Dejonckheere6, Bradford H Challis7, Rossella Medori81Department of Psychiatry, University Medical Center, St. Radboud and Karakter Child and Adolescent Psychiatry Universit...
Main Authors: | Jan K Buitelaar, J Antoni Ramos-Quiroga, Miguel Casas, et al |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2009-08-01
|
Series: | Neuropsychiatric Disease and Treatment |
Online Access: | http://www.dovepress.com/safety-and-tolerability-of-flexible-dosages-of-prolonged-release-oros--a3483 |
Similar Items
-
Comparative acute efficacy and tolerability of OROS and immediate release formulations of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder
by: Hammerness Paul, et al.
Published: (2007-09-01) -
The effect of methylphenidate-OROS<sup>®</sup> on the narrative ability of children with attention-deficit hyperactivity disorder
by: Tessa L. Rausch, et al.
Published: (2017-02-01) -
Methylphenidate use in children with attention deficit hyperactivity disorder
by: Felipe Salles Neves Machado, et al.
Published: (2015-01-01) -
Modified-release methylphenidate-induced Raynaud’s phenomenon in an adolescent with attention deficit hyperactivity disorder
by: Ali Karayağmurlu, et al.
Published: (2022-09-01) -
Cost-effectiveness of extended-release methylphenidate in children and adolescents with attention-deficit/hyperactivity disorder sub-optimally treated with immediate release methylphenidate.
by: Jurjen van der Schans, et al.
Published: (2015-01-01)